302 related articles for article (PubMed ID: 26319783)
41. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.
Bai Y; Wong KY; Fung TK; Chim CS
J Hematol Oncol; 2016 Oct; 9(1):107. PubMed ID: 27724958
[TBL] [Abstract][Full Text] [Related]
42. A comparison of DNA methylation specific droplet digital PCR (ddPCR) and real time qPCR with flow cytometry in characterizing human T cells in peripheral blood.
Wiencke JK; Bracci PM; Hsuang G; Zheng S; Hansen H; Wrensch MR; Rice T; Eliot M; Kelsey KT
Epigenetics; 2014 Oct; 9(10):1360-5. PubMed ID: 25437051
[TBL] [Abstract][Full Text] [Related]
43. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission.
Sato M; Yamazaki J; Goto-Koshino Y; Setoguchi A; Takahashi M; Baba K; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2016 Sep; 215():38-42. PubMed ID: 27339366
[TBL] [Abstract][Full Text] [Related]
44. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards.
Gerard CJ; Olsson K; Ramanathan R; Reading C; Hanania EG
Cancer Res; 1998 Sep; 58(17):3957-64. PubMed ID: 9731509
[TBL] [Abstract][Full Text] [Related]
45. Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Quelen C; Grand D; Sarot E; Brugières L; Sibon D; Pradines A; Laurent C; Brousset P; Lamant L
J Mol Diagn; 2021 Feb; 23(2):131-139. PubMed ID: 33246076
[TBL] [Abstract][Full Text] [Related]
46. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
Pulsoni A; Della Starza I; Cappelli LV; Tosti ME; Annechini G; Cavalli M; De Novi LA; D'Elia GM; Grapulin L; Guarini A; Del Giudice I; Foà R
Br J Haematol; 2020 Jan; 188(2):249-258. PubMed ID: 31385309
[TBL] [Abstract][Full Text] [Related]
47. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
48. Molecular monitoring of minimal residual disease in patients with multiple myeloma.
Fenk R; Haas R; Kronenwett R
Hematology; 2004 Feb; 9(1):17-33. PubMed ID: 14965865
[TBL] [Abstract][Full Text] [Related]
49. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Assanto GM; Del Giudice I; Della Starza I; Soscia R; Cavalli M; Cola M; Bellomarino V; Di Trani M; Guarini A; Foà R
Front Oncol; 2023; 13():1152467. PubMed ID: 36998457
[TBL] [Abstract][Full Text] [Related]
50. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.
Schmitt C; Balogh B; Grundt A; Buchholtz C; Leo A; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Jun; 30(6):745-50. PubMed ID: 16297448
[TBL] [Abstract][Full Text] [Related]
51. [Complex diagnosis of follicular lymphomas].
Tóth E; Schneider T; Melegh Z; Csernák E; Udvarhelyi N; Rosta A; Szentirmay Z
Magy Onkol; 2005; 49(2):135-40. PubMed ID: 16249809
[TBL] [Abstract][Full Text] [Related]
52. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
53. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
[TBL] [Abstract][Full Text] [Related]
54. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
55. Response monitoring in follicular lymphoma by synchronous evaluation of minimal residual disease and diffusion-weighted MRI.
Meleshko AN; Kharuzhyk SA; Piatrouskaya NA
Exp Oncol; 2015 Dec; 37(4):295-7. PubMed ID: 26710844
[TBL] [Abstract][Full Text] [Related]
56. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.
Chovancová J; Bernard T; Stehlíková O; Šálek D; Janíková A; Mayer J; Doubek M
Cytometry B Clin Cytom; 2015 Mar; 88(2):92-100. PubMed ID: 25586981
[TBL] [Abstract][Full Text] [Related]
57. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.
Hirt C; Schüler F; Dölken G
Semin Cancer Biol; 2003 Jun; 13(3):223-31. PubMed ID: 12959353
[TBL] [Abstract][Full Text] [Related]
58. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
Nakao M; Janssen JW; Flohr T; Bartram CR
Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
[TBL] [Abstract][Full Text] [Related]
59. [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
al Saati T; Galoin S; Roda D; Huynh A; Attal M; Delsol G
Bull Cancer; 1998 Oct; 85(10):847-54. PubMed ID: 9835862
[TBL] [Abstract][Full Text] [Related]
60. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]